The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs' original purpose, which was to treat Type 2 diabetes, a new study ... use as a weight-loss ...

A new report based on national prescription data shows weight ... loss. A study by the Evernorth Research Institute looking at national prescription drug use trends found GLP-1 use between 2023 ...

For the study, researchers analyzed the ... There has been a notable uptick in GLP-1 use since 2020, Rezaie noted. The U.S. Food and Drug Administration approved semaglutide for use as a weight ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered ... highest dose of the drug scored an A1C less ...

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4% in 2022. As a result, annual spending jumped from $1.6 billion to $5. ...

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows. Not only is ...

"This large cohort study ... 0.83-1.25). "Because of GLP-1s' known side effect of pancreatitis, there's been some concern about links between GLP-1 use and pancreatic cancer. And this just shows ...